2025-06-10-Jefferies-维罗纳（VRNA）_管理层晚宴_新型慢性阻塞性肺疾病雾化器有望成为30_-_50亿美元以上的重磅药物_15页_454kb

Verona Pharma (VRNA) Equity Research Summary

** $110.00 PT**

Rating: Buy
Price Target: $110.00
Sales Target: Revised $3B peak estimate (previously $3B); FY25 revenue estimate $406M.
Market Cap: $7.1B (6/10/2025)

Product: Ohtuvayre

• Novel PDE3/4 inhibitor nebulizer for COPD added to all existing therapies.
• Placebo-like safety and dyspnea benefits.
• Q1 2025 sales: $71M (up +95% YoY from $37M Q4 2024); beats consensus.
• Launched in August 2024; mgmt views it as a multi-billion dollar opportunity.
• Ohtuvayre is being marketed as the first novel COPD agent approved in decades.

Market and Growth

• Large US patient opportunity (8.5M+ patients, $14B+ market for severe COPD).
• COPD launch trajectories historically linear but mgmt believes Ohtuvayre’s growth could be parabolic.
• Sales momentum driven by:
  • Expansion into non-CF bronchiectasis (Phase II data in 2026-27).
  • LAMA+Ensi Phase IIb trial in H2 2025.
  • Effective physician education and data-driven refill management.
• 50% of Ohtuvayre patients on background singles/duals (not triples), indicating upstream movement.
• Favorable Medicare Part B pathway and specialty pharmacy access.
• Growth accelerated by +30 sales rep expansion (to 150) in July 2025.

Financials

• Q2 2025 EPS expected to be $0.04; mgmt achievinq profitability in Q2 2025.
• FY25 revenue guidance: $406M, above consensus $404M.
• DCF-based PT assumes a 9% discount rate and 3-4x multiple on sales.
• Cash reserves ~$400M; disciplined $48M Oaktree facility.

Future Outlook

• Potential bolt-on acquisitions or partnerships, e.g., in asthma or CF.
• Long-term focus on becoming a leader in pulmonology with respiratory pipeline.
• Biologics unlikely to compete directly due to subpopulation targeting; Ohtuvayre’s broad utility is key.
• Risk management: Intellectual property extension via LAMA+Ensi combo could impact pricing.

Risks and Opportunities

• Competition: Biologics like itepekimab years away; Ohtuvayre additive, not competitive.
• Access/Regulatory: Requires ongoing regulatory clarity for overseas filings; ex-US partnerships promising.
• Positive catalysts: Guidance updates, Phase II data launches, and continued prescriber adoption.
• Analyst views: Ohtuvayre growth potential could lead to valuation near $9B-15B.

DISCLAIMER:

• Summary based on analyst reports from Jefferies dated June 10, 2025.
• Use for informational purposes only; investors should conduct their own due diligence.